GRAPE KING BIO LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 160 TWD | +0.31% |
|
-0.31% | +2.56% |
| Feb. 27 | Grape King Bio Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 09 | Grape King Bio Hits Record-High Sales of NT$10.64 Billion in 2023 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.56% | 735M | - | ||
| +16.86% | 8.48B | D+ | ||
| +5.05% | 7.6B | C- | ||
| +4.89% | 6.39B | - | ||
| -5.23% | 3.75B | B- | ||
| -6.58% | 3.71B | D | ||
| -3.55% | 1.36B | - | - | |
| -28.64% | 1.11B | B+ | ||
| +18.12% | 1.02B | - | ||
| -8.60% | 924M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 1707 Stock
- Ratings Grape King Bio Ltd
